Isocombretastatins A versus combretastatins A: The forgotten isoCA-4 isomer as a highly promising cytotoxic and antitubulin agent

Journal of Medicinal Chemistry

Volumn 52, Issue 14, 2009, Pages 4538-4542

  Messaoudi, Samir ^a   Tréguier, Bret ^a   Hamze, Abdallah ^a   Provot, Olivier ^a   Peyrat, Jean François ^a   De Losada, Jordi Rodrigo ^a   Liu, Jian Miao ^b   Bignon, Jérôme ^b   Wdzieczak Bakala, Joanna ^b   Thoret, Sylviane ^b   Dubois, Joelle ^b   Brion, Jean Daniel ^a   Alami, Mouâd ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b INSTITUT DE CHIMIE DES SUBSTANCES NATURELLES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMBRETASTATIN; COMBRETASTATIN A4; ISOCOMBRETASTATIN A; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE ARREST; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG STRUCTURE;

ANTINEOPLASTIC AGENTS; BIBENZYLS; CELL LINE, TUMOR; CELL PROLIFERATION; CHLOROPHENOLS; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PEPTIDES, CYCLIC; STEREOISOMERISM; TUBULIN MODULATORS;

EID: 67650760201     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900321u     Document Type: Article

References (26)

1. Alami, M.; Brion, J.-D.; Provot, O.; Peyrat, J.-F.; Messaoudi, S.; Hamze, A.; Giraud, A.; Bignon, J.; Bakala, J.; Liu, J.-M. IsoCA-4 and analogues thereof as potent cytotoxic agents inhibiting tubulin polymerization. Patent WO 122620 A1, 2008.
2. Hadfield, J. A.; Ducki, S.; Hirst, N.; McGown, A. T. Tubulin and microtubules as targets for anticancer drugs. Prog. Cell Cycle Res. 2003, 5, 309-325.
3. Schiff, P. B.; Fant, J.; Horwitz, S. B. Promotion of microtubule assembly in vitro by taxol. Nature 1979, 277, 665-667.
4. Bhattacharayya, B.; Panda, D.; Gupta, S.; Banerjee, M. Antimitotic activity of colchicine and the structural basis for its interaction with tubulin. Med. Res. Rev. 2008, 28, 155-183.
5. Jordan, M. A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr. Med. Chem. Anticancer Agents 2002, 1, 1-17.
6. (a) Pettit, G. R.; Singh, S. B.; Niven, M. L.; Hamel, E.; Schmidt, J. M. Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J. Nat. Prod. 1987, 50, 119-131.
7. (b) Pettit, G. R.; Singh, S. B. Isolation, structure, and synthesis of combretastatin A-2, A-3, and B-2. Can. J. Chem. 1987, 65, 2390-2396.
8. (c) Pettit, G. R.; Singh, S. B.; Boyd, M. R.; Hamel, E.; Pettit, R. K.; Schmidt, J. M.; Hogan, F. Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6. J. Med. Chem. 1995, 38, 1666-1672.
9. Tozer, G. M.; Kanthou, C.; Parkins, C. S.; Hill, S. A. The biology of the combretastatins as tumour vascular targeting agents. Int. J. Exp. Pathol. 2002, 83, 21-38.
10. Siemann, D. W.; Chaplin, D. J.; Walicke, P. A. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin. Investig. Drugs 2009, 18, 189-197.
11. (a) Patterson, D. M.; Rustin, G. J. S. Combretastatin A-4 phosphate. Drugs Future 2007, 32, 1025-1032.
12. (b) Lippert, J. W. Vascular disrupting agents. Bioorg. Med. Chem. 2007, 15, 605-615.
13. Tron, G. C.; Pirali, T.; Sorba, G.; Pagliai, F.; Dusacca, S.; Genazzani, A. A. Medicinal chemistry of combretastatin A4: present and future directions. J. Med. Chem. 2006, 49, 3033-3044.
14. Pettit, G. R.; Toki, B.; Herald, D. L.; Boyd, M. R.; Hamel, E.; Pettit, R. K.; Chapuis, G. C. Antineoplastic Agents. Asymmetric Hydroxylation of trans-Combretastatin A-4. J. Med. Chem. 1999, 42, 1459-1465.
15. Pettit, G. R.; Toki, B.; Herald, D. L.; Verdier-Pinard, P.; Boyd, M. R.; Hamel, E.; Pettit, R. K. Antineoplastic agents. 379. Synthesis of phenstatin phosphate. J. Med. Chem. 1998, 41, 1688-1695.
16. (a) Provot, O.; Giraud, A.; Peyrat, J.-F.; Alami, M.; Brion, J.-D. Synthetic approach to enyne and enediyne analogues of anticancer agents. Tetrahedron Lett. 2005, 46, 8547-8550.
17. (b) Mousset, C.; Giraud, A.; Provot, O.; Hamze, A.; Bignon, J.; Liu, J. M.; Thoret, S.; Dubois, J.; Brion, J.-D.; Alami, M. Synthesis and antitumor activity of benzils related to combretastatin A-4. Bioorg. Med. Chem. Lett. 2008, 18, 3266-3271.
18. Barluenga, J.; Moriel, P.; Valdés, C.; Aznar, F. N-Tosylhydrazones as reagents for cross-coupling reactions: a route to polysubstituted olefins. Angew. Chem., Int. Ed. 2007, 46, 5587-5590.
19. Giraud, A.; Provot, O.; Hamze, A.; Brion, J. D.; Alami, M. Onepot hydrosilylation-protodesilylation of functionalized diarylalkynes: a highly selective access to Z-stilbenes. Application to the synthesis of combretastatin A-4. Tetrahedron Lett. 2008, 49, 1107-1110.
20. Patani, G. A.; LaVoie, E. J. Bioisosterism: a rational approach in drug design. Chem. Rev. 1996, 96, 3147-3176.
21. Nguyen, T. L.; McGrath, C.; Hermone, A. R.; Burnett, J. C.; Zaharevitz, D. W.; Day, B. W.; Wipf, P.; Hamel, E.; Gussio, R. A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach. J. Med. Chem. 2005, 48, 6107-6116.
22. Lara-Ochoa, F.; Espinosa-Pérez, G. A new synthesis of combretastatins A-4 and AVE-8062. Tetrahedron Lett. 2007, 48, 7007-7010.
23. Ravelli, R. B.; Gigant, B.; Curmi, P. A.; Jourdain, I.; Lachkar, S.; Sobel, A.; Knossow, M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004, 198-202.
24. Ohsumi, K.; Nakagawa, R.; Fukuda, Y.; Hatanaka, T.; Morinaga, Y.; Nihei, Y.; Ohishi, K.; Suga, Y.; Akiyama, Y.; Tsuji, T. Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships. J. Med. Chem. 1998, 41, 3022-3032.
25. Alloatti, D.; Giannini, G.; Cabri, W.; Lustrati, I.; Marzi, M.; Ciacci, A.; Gallo, G.; Tinti, M. O.; Marcellini, M.; Riccioni, T.; Guglielmi, M. B.; Carminati, P.; Pisano, C. Synthesis and biological activity of fluorinated combretastatin analogues. J. Med. Chem. 2008, 51, 2708-2721.
26. Zhang, L.-H.; Wu, L.; Raymon, H. K.; Chen, R. S.; Corral, L.; Shirlei, M. A.; Narla, R. K.; Gamez, J.; Muller, G. W.; Stirling, D. I.; Bartlett, J. B.; Schafer, P. H.; Payvandi, F. The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-R production with antitumor activity. Cancer Res. 2006, 66, 951-959.